Takeda has a strong legacy in developing treatments for lysosomal storage disorders (LSDs), with a portfolio that includes commercial products, late-stage investigational therapies, and pipeline candidates. Because rare genetic and metabolic diseases can have symptoms that vary widely and progress differently from person to person, we empower global education and awareness, and partner with medical and research organisations. We are committed to helping reduce the amount of time between the onset of symptoms and diagnosis, and to accelerating the development of innovative new treatments.

 

C-ANPROM/INT//7574; Date of preparation: September 2020